BG Medicine, Inc. (BGMD) to Present on Galectin-3 at 2012 American Heart Association Meeting

BG Medicine is a life sciences company focused on the discovery, development, and commercialization of novel cardiovascular diagnostics. The company’s first commercial product, the BGM Galectin-3 Test, is for use in patients with heart failure and is available in both the United States and Europe.

The company announced today that it will be launching a major initiative to help hospitals reduce the number of unplanned readmissions for heart failure patients. The initiative will begin at the American Heart Association Scientific Sessions 2012 taking place November 3-7 in Los Angeles. Representatives at the BG Medicine booth (#1737) will be there to highlight the role that Galectin-3 blood testing can play in helping the medical community address the urgent need to reduce hospital readmission rates.

Currently, even with optimal care, nearly a one-fourth of all Medicare heart failure patients are readmitted to the hospital within 30 days. This makes heart failure a major factor of hospital readmission rates, far ahead of heart attack and pneumonia. Because heart failure patients with elevated galectin-3 levels are two-to-three times more likely to be readmitted within 30 days to a hospital, identifying these high risk patients through galectin-3 testing is a potentially valuable and cost-effective in combating these readmissions.

BG Medicine believes the company will benefit and be able to grow the market for its Galectin-3 Test thanks to recent government rulings. Effective October 1, 2012, new rules from the federal Centers for Medicare & Medicaid Services have made reducing unplanned hospital readmissions a critical priority. Hospitals that exceed the Medicare thresholds will be assessed financial penalties that may reach $1 billion by 2015, if improvements are not made.

For additional information about BG Medicine and its Galectin-3 Test, visit www.bg-medicine.com

About MissionIR 

MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.

Sign up for “The Mission Report” at www.MissionIR.com

Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html